MedTrace Logo

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

NCT03708224 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-01-28

No results posted yet for this study

Summary

To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.

Conditions

Interventions

BIOLOGICAL

Atezolizumab

Given intravenously (IV)

BIOLOGICAL

Tocilizumab

Given IV

BIOLOGICAL

Tiragolumab

Given IV

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • American Head and Neck Society

    collaborator OTHER

  • Alain Algazi

    lead OTHER

Principal Investigators

  • Alain Algazi, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-08
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03708224 on ClinicalTrials.gov